Polymer factor IX moiety conjugates
AssigneeNektar Therapeutics AL, Corporation
InventorsMary Bossard, Gayle Stephenson
Life of this patent
Estimating the term…
Abstract
Conjugates of a Factor IX moiety and one or more water-soluble polymers are provided. Typically, the water-soluble polymer is poly(ethylene glycol) or a derivative thereof. Also provided (among other things) are compositions comprising the conjugates, methods of making the conjugates, and methods of administering to a patient compositions comprising the conjugates.
Claims21
A conjugate comprising a Factor IX moiety covalently attached, either directly or through a spacer moiety comprised of one or more atoms, to a water-soluble polymer, wherein the molecular weight of the water-soluble polymer is greater than 5,000 Daltons and less than about 150,000 Daltons.
A conjugate comprising a Factor IX moiety covalently attached at an amino acid residue, either directly or through a spacer moiety comprised of one or more atoms, to a water-soluble polymer, wherein the amino acid residue is not attached, either directly or though the spacer moiety, via a —CH2—C(O)—O—, —N(H)—C(O)CH2—O—, —C(O)—N(H)—, —N(H)—C(O)—CH2—O—, —C(O)—CH2—O—, —C(O)—CH2—CH2—C(O)—O—, diazo, or triazine linkage.
A conjugate comprising a Factor IX moiety covalently attached, either directly or through a spacer moiety comprising of one or more atoms, to a non-linear water-soluble polymer.
21-62. (canceled)
Dependencies are inferred from the claim text.